Cell & Gene Therapy · Bioprocessing
MaxCyte news and milestones
MaxCyte: 10 headlines on record, 4 headlines in the last 90 days. Its story counts 5 milestones.
Data updated Nov 20, 2026 · Back to the company report
10Headlines
4In 90 days
5Milestones
Headlines
Oct 72026
News · MaxCyte stock gained 0.9 percent as revenue fell 15 percent
MaxCyte stock was last at USD 1.08 on October 6, 2026, while six analysts set a USD 4.108 average target. Second-quarter revenue reached USD 7.3 million.
Sep 242026
News · MaxCyte stock slips 4.03 percent as new chief arrives
MaxCyte stock carried a USD 127,474,790 market value on September 23, 2026. Q2 revenue fell 15 percent to USD 7.3 million, while 2026 guidance held.
Sep 232026
News · markets.businessinsider.com
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform ...
Sep 232026
News · MaxCyte stock falls as revenue and market value remain under pressure
MaxCyte stock traded at USD 1.17 on September 22, 2026, down 2.5 percent with a USD 120.24 million market value. Revenue was USD 33.03 million.
Sources: the outlets named on each headline, each story once
Milestones
2025
Team of 108 was 96 · US Form 5500 (plan participants)
Mar 29, 2016
1999
Founded
Each milestone is dated by its source: registers, filings, the press
How to cite
MaxCyte, News. Alion, Nov 20, 2026. https://alion.io/company/maxcyte/news
